−1.84USD
−15.42 MUSD
5.90 M
About Indaptus Therapeutics, Inc.
Sector
CEO
Jeffrey A. Meckler
Headquarters
New York
Website
Employees (FY)
7
ISIN
US45339J1051
FIGI
BBG00ZNLVBC8
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of INDP is 2.36 USD — it has decreased by 6.35% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Indaptus Therapeutics, Inc. stocks are traded under the ticker INDP.
Indaptus Therapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
INDP stock is 9.19% volatile and has beta coefficient of 1.90. Check out the list of the most volatile stocks — is Indaptus Therapeutics, Inc. there?
One year price forecast for Indaptus Therapeutics, Inc. has a max estimate of 12.00 USD and a min estimate of 8.00 USD.
INDP earnings for the last quarter are −0.47 USD per share, whereas the estimation was −0.52 USD resulting in a 9.62% surprise. The estimated earnings for the next quarter are −0.54 USD per share. See more details about Indaptus Therapeutics, Inc. earnings.
Indaptus Therapeutics, Inc. revenue for the last quarter amounts to 0 USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach 750.00 K USD.
Yes, you can track Indaptus Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
INDP stock has fallen by 13.87% compared to the previous week, the month change is a 11.32% rise, over the last year Indaptus Therapeutics, Inc. has showed a 21.07% decrease.
INDP net income for the last quarter is −4.00 M USD, while the quarter before that showed −3.92 M USD of net income which accounts for −2.05% change. Track more Indaptus Therapeutics, Inc. financial stats to get the full picture.
Today Indaptus Therapeutics, Inc. has the market capitalization of 21.52 M, it has increased by 1.92% over the last week.
No, INDP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, INDP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Indaptus Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 20, 2024, the company has 7.00 employees. See our rating of the largest employees — is Indaptus Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Indaptus Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Indaptus Therapeutics, Inc. stock shows the neutral signal. See more of Indaptus Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Indaptus Therapeutics, Inc. future price: according to them, INDP price has a max estimate of 12.00 USD and a min estimate of 8.00 USD. Read a more detailed Indaptus Therapeutics, Inc. forecast: see what analysts think of Indaptus Therapeutics, Inc. and suggest that you do with its stocks.